AIRLINK 74.00 Decreased By ▼ -0.25 (-0.34%)
BOP 5.14 Increased By ▲ 0.09 (1.78%)
CNERGY 4.55 Increased By ▲ 0.13 (2.94%)
DFML 37.15 Increased By ▲ 1.31 (3.66%)
DGKC 89.90 Increased By ▲ 1.90 (2.16%)
FCCL 22.40 Increased By ▲ 0.20 (0.9%)
FFBL 33.03 Increased By ▲ 0.31 (0.95%)
FFL 9.75 Decreased By ▼ -0.04 (-0.41%)
GGL 10.75 Decreased By ▼ -0.05 (-0.46%)
HBL 115.50 Decreased By ▼ -0.40 (-0.35%)
HUBC 137.10 Increased By ▲ 1.26 (0.93%)
HUMNL 9.95 Increased By ▲ 0.11 (1.12%)
KEL 4.60 Decreased By ▼ -0.01 (-0.22%)
KOSM 4.83 Increased By ▲ 0.17 (3.65%)
MLCF 39.75 Decreased By ▼ -0.13 (-0.33%)
OGDC 138.20 Increased By ▲ 0.30 (0.22%)
PAEL 27.00 Increased By ▲ 0.57 (2.16%)
PIAA 24.24 Decreased By ▼ -2.04 (-7.76%)
PIBTL 6.74 Decreased By ▼ -0.02 (-0.3%)
PPL 123.62 Increased By ▲ 0.72 (0.59%)
PRL 27.40 Increased By ▲ 0.71 (2.66%)
PTC 13.90 Decreased By ▼ -0.10 (-0.71%)
SEARL 61.75 Increased By ▲ 3.05 (5.2%)
SNGP 70.15 Decreased By ▼ -0.25 (-0.36%)
SSGC 10.52 Increased By ▲ 0.16 (1.54%)
TELE 8.57 Increased By ▲ 0.01 (0.12%)
TPLP 11.10 Decreased By ▼ -0.28 (-2.46%)
TRG 64.02 Decreased By ▼ -0.21 (-0.33%)
UNITY 26.76 Increased By ▲ 0.71 (2.73%)
WTL 1.38 No Change ▼ 0.00 (0%)
BR100 7,874 Increased By 36.2 (0.46%)
BR30 25,596 Increased By 136 (0.53%)
KSE100 75,342 Increased By 411.7 (0.55%)
KSE30 24,214 Increased By 68.6 (0.28%)
Technology

Startup aims to use gene-editing technology to treat heart diseases

In order to help treat lethal heart diseases, a new startup has proposed a plan to use the latest gene-editing tech
Published May 8, 2019

In order to help treat lethal heart diseases, a new startup has proposed a plan to use the latest gene-editing technology for achieving the goal.

Genetics already play a great role in figuring out people’s risk of developing heart disease or having a heart attack. A new biotech startup Verve Therapeutics has come up with an innovative plan to use CRISPR gene-editing technology to put an end to heart diseases.

CRISPR gene-editing includes a process by which genes are cut out of or inserted into a person’s DNA strand. As per Futurism, the firm’s plan is to use CRISPR in order to edit genes of adults with a greater genetic risk of heart problems so that they more closely resemble the genes of people with a naturally low risk of such ailments.

Researchers use gene-editing technology to treat fatal lung disease before birth

“Poor adherence, costs, side effects, limited access… all these challenges have limited the impact existing heart medications like cholesterol-lowering statins have had,” Sekar Kathiresan, Verve’s CEO, told Reuters.

The firm is currently exploring seven various genes that scientists have found leave people with a natural resistance to coronary artery disease. It plans to select one or two genes over the next year in order to initiate clinical trials. Verve believes that interesting one gene into a person’s DNA will permanently lower their bad cholesterol and cut down their livelihood of having a heart attack, as per Boston Business Journal.

“With our therapy, we could change the treatment paradigm for heart disease from chronic care, daily pills, or monthly injections to a one-and-done approach,” Kathiresan asserted.

Moreover, the Verve Therapeutics soon enough found a major firm to back it up. As per the firm, it had raised $58.5 million in financing, most of which came through GV (Google Ventures), the venture capital arm of Google’s parent company Alphabet.

“[Verve] has broad potential to address the number one leading cause of death in the world unlike anything we’ve seen before,” GV general partner Krishna Yeshwant said.

Copyright Business Recorder, 2019

Comments

Comments are closed.